Literature DB >> 21917455

Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists.

Tatsuhiko Fujimoto1, Jun Kunitomo, Yoshihide Tomata, Keiji Nishiyama, Masato Nakashima, Mariko Hirozane, Shin-Ichi Yoshikubo, Keisuke Hirai, Shogo Marui.   

Abstract

During our efforts to identify a series of potent, selective, orally active human Orexin-2 Receptor (OX2R) antagonists, we elucidated structure-activity relationship (SAR) on the 7-position of a benzoxazepine scaffold by utilizing Hammett σ(p) and Hansch-Fujita π value as aromatic substituent constants. The attempts led to the discovery of compound 1m, possessing good in vitro potency with over 100-fold selectivity against OX1R, good metabolic stability in human and rat liver microsome, good oral bioavailability in rats, and in vivo antagonistic activity in rats by oral administration.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917455     DOI: 10.1016/j.bmcl.2011.08.093

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Stereodivergent access to all four stereoisomers of chiral tetrahydrobenzo[f][1,4]oxazepines, through highly diastereoselective multicomponent Ugi-Joullié reaction.

Authors:  Alessandro Pinna; Andrea Basso; Chiara Lambruschini; Lisa Moni; Renata Riva; Valeria Rocca; Luca Banfi
Journal:  RSC Adv       Date:  2020-01-03       Impact factor: 3.361

2.  Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice.

Authors:  Keishi Etori; Yuki C Saito; Natsuko Tsujino; Takeshi Sakurai
Journal:  Front Neurosci       Date:  2014-01-31       Impact factor: 4.677

3.  Toward an understanding of agonist binding to human Orexin-1 and Orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesis.

Authors:  Alexander Heifetz; Oliver Barker; G Benjamin Morris; Richard J Law; Mark Slack; Philip C Biggin
Journal:  Biochemistry       Date:  2013-11-08       Impact factor: 3.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.